Reporting owner · CIK 0002004380

Lippis Daniel J.

SEC Form 4 history across 1 companies, 20 transactions and 5 filings.

CVP, TAVRCVP, TAVREdwards Lifesciences Corp
Open-market transaction mix0% buys0 buys · 5 sales

Available history · May 01, 2026 – Oct 08, 2026

Filings5Form 4 records
Buying$00 purchases
Selling$277.3K5 sales
Net value−$277.3KBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Lippis Daniel J. transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedDerivative securitySEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRS · sale10b5-1 detectedSEC filing ↗-$53.0kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedSEC filing ↗$44.9kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedDerivative securitySEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRS · sale10b5-1 detectedSEC filing ↗-$54.1kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedSEC filing ↗$44.9kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRF · withholdingSEC filing ↗-$28.9kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRA · grantDerivative securitySEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRA · grantDerivative securitySEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRF · withholdingSEC filing ↗-$37.2kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRF · withholdingSEC filing ↗-$25.7kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRA · grantSEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedDerivative securitySEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedDerivative securitySEC filing ↗$0View disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRS · sale10b5-1 detectedSEC filing ↗-$85.5kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedSEC filing ↗$60.3kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRF · withholding10b5-1 detectedSEC filing ↗-$21.1kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRS · sale10b5-1 detectedSEC filing ↗-$82.9kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRS · sale10b5-1 detectedSEC filing ↗-$1.59kView disclosure →
EWEdwards Lifesciences Corp
Lippis Daniel J.CVP · TAVRM · exercise10b5-1 detectedSEC filing ↗$60.3kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

sale at Edwards Lifesciences Corp on Oct 08, 2026 valued at $53,017.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Edwards Lifesciences Corp on Oct 08, 2026 valued at $53,017.

Review SEC filing

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202603$0.00$170,160.29-$170,160.29
Sep 202601$0.00$54,168.69-$54,168.69
Oct 202601$0.00$53,017.35-$53,017.35

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$55.5K
Median P/S size$54.2K
Direct20
Indirect0
Oct 08, 2026exercise

Associated companies

Companies in the disclosed reporting history

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in available history

A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

14 observations · May 1, 2026 – Oct 8, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 8, 202640033.910300 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
May 1, 202634952.910300May 4, 2026View transaction
May 1, 202634933.910300May 4, 2026View transaction
May 1, 202633933.910300May 4, 2026View transaction
May 3, 202633681.910300May 4, 2026View transaction
May 4, 202634700.910300May 4, 2026View transaction
May 4, 202633681.910300May 4, 2026View transaction
May 7, 202641531.910300May 9, 2026View transaction
May 7, 202641222.910300May 9, 2026View transaction
May 8, 202640772.910300May 9, 2026View transaction
May 11, 202640410.910300May 12, 2026View transaction
Sep 11, 202640652.910300Sep 11, 2026View transaction
Sep 11, 202640033.910300Sep 11, 2026View transaction
Oct 8, 202640652.910300Oct 8, 2026View transaction
Oct 8, 202640033.910300Oct 8, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Lippis Daniel J. Insider Activity FAQ

SEC Form 4 context

Who is Lippis Daniel J.?

Lippis Daniel J. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002004380.

Which companies has Lippis Daniel J. reported transactions for?

Edwards Lifesciences Corp

When was Lippis Daniel J.'s latest insider buy?

No open-market insider purchase is available for this period.

When was Lippis Daniel J.'s latest insider sale?

sale at Edwards Lifesciences Corp on Oct 08, 2026 valued at $53,017.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.